Simon Rule, MD and Mathias Rummel, MD, PhD
In this segment, “On the Horizon for MCL”, Simon Rule, MD and Mathias Rummel, MD, PhD discuss recent advances in mantle cell lymphoma (MCL) and clinical implications for the future.
Bruton’s tyrosine kinase (BTK) inhibitors – ibrutinib and acalabrutinib – are currently used for relapsed/refractory MCL and are poised to move into first-line. The BTK inhibitors are similar in many ways, but there are some differences that could influence treatment choice. Clearly, P53 mutations have a big prognostic impact in MCL, suggesting a role for allogeneic transplantation and/or novel agent combinations in these patients. Also, the combination of rituximab, bendamustine and cytarabine (R-BAC) is showing promise as a new salvage therapy.